Search Bar & Filters
Found 2 Actively Recruiting clinical trials
Actively Recruiting
Neuroendocrine tumours NETs are slow-growing cancers often found in the gut that can spread to organs like the liver, bones, and lymph nodes. Many NETs do not produce excess hormones, and their main treatment is somatostatin analogues SSA, which slow tumour growth and reduce hormone production. Over time, most patients experience tumour growth despite SSA therapy. This study investigates whether continuing SSA treatment after starting Peptide Receptor Radionuclide Therapy PRRT, a targeted radiotherapy, benefits patients with grade 1 and 2 well-differentiated mid, hind-gut, or pancreatic NETs that have progressed on SSA therapy. Participants will be randomly assigned to one of two groups those who continue SSA injections during and after PRRT, and those who stop SSA after receiving their last injection before starting PRRT. PRRT is given as the next treatment step for patients with inoperable metastatic NETs who have shown progression despite SSA therapy. The study aims to estimate the 20-month progression-free survival rate for both groups and assess feasibility factors like recruitment and patient acceptance of stopping SSA. During the study, patients will receive PRRT and either continue or cease SSA injections according to their group assignment. Researchers will monitor tumour progression, quality of life, cost-effectiveness, psychological impacts, overall survival, and the timing of any further treatments over 20 months. Study assessments include imaging scans, performance status evaluations, and collection of clinical data. This trial is open-label and will help clarify the role of continuing SSA therapy alongside PRRT in this patient population.
Actively Recruiting
This observational study focuses on people living with chronic hepatitis B in Australia. It aims to characterize and monitor how individuals link to care and their treatment needs across a wide network of healthcare services. The study is sponsored by the Kirby Institute and seeks to understand various aspects of hepatitis B management in a real-world setting. Participants are individuals diagnosed with chronic hepatitis B who have attended participating clinics for hepatitis B care within the past 12 months or are attending from the study start. There is no intervention as this is an observational study. Data collected includes demographics, lab results, liver disease assessments, treatment history, and clinical management details. Follow-up data will be gathered at each visit or at least every 12 months. During the study, participants will have their hepatitis B treatment and clinical management monitored regularly. Researchers will evaluate outcomes such as hepatitis B disease stage, treatment adherence, liver fibrosis progression, and surveillance for liver cancer. The study plans to collect data until July 2027, with ongoing observation to understand disease progression and care patterns over time.